Nucleic acid thermodynamics

Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer

Retrieved on: 
Friday, April 5, 2024
Lung cancer, Liquid biopsy, Nucleic acid thermodynamics, Patient, NGS, Deletion, Blood, DNA, Urine, BDD, NSCLC, Food

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced a collaboration with Apollomics, Inc.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced a collaboration with Apollomics, Inc.
  • This collaboration aims to advance the development of PredicineCARE™, a blood cell-free DNA (cfDNA) next-generation sequencing (NGS) assay, to identify non-small cell lung cancer (NSCLC) patients who may benefit from targeted therapy.
  • PredicineCARE™ was granted Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration on August 23, 2022.
  • PredicineCARE™ is a comprehensive, state-of-the-art NGS assay that interrogates point mutations/indels, fusions, amplifications, and deletions in key cancer-associated genes using cfDNA from liquid biopsy samples such as blood and urine.

Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing

Retrieved on: 
Friday, April 5, 2024
CDX, Nucleic acid thermodynamics, Tissue, NGS, DNA, RUO, Laboratory, Urine, BDD, Cancer, Liquid biopsy, Deletion, Blood, FDA, Food

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.
  • This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.
  • This newly introduced PredicineCARE™ NGS kit integrates a comprehensive, state-of-the-art NGS assay capable of detecting point mutations, indels, fusions, amplifications, and deletions in key cancer-associated genes.
  • “Predicine’s centralized global lab network coupled with the decentralized kitted offering provides a standardized approach to support clinical trials, CDx development and patient testing on a global scale.”

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Other Health, Health, General Health, Oncology, Health Technology, Medical Devices, Research, Genetics, Science, Clinical Trials, Prostate cancer, Survival, Nucleic acid thermodynamics, Methylation, Cancer, MD, Medicine, AACR, Gene expression, Molecular biology, Medical imaging

“The data we are presenting at AACR continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,” said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL.

Key Points: 
  • “The data we are presenting at AACR continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,” said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL.
  • Exhibiting 4-year overall survival follow-up demonstrating the prognostic significance of detecting cancer with a methylation-based cfDNA platform like Galleri.
  • Illustrating data demonstrating the power of Galleri to preferentially detect high grade, clinically significant prostate cancer over indolent cases.
  • In the precision oncology setting, GRAIL will discuss the adaptability of its Methylation Platform in identifying cancer histological and molecular subtypes through blood samples.

New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors

Retrieved on: 
Tuesday, March 26, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Plasma, Novartis, Nucleic acid thermodynamics, Patient, Biomarker, DNA, Cancer, Virtuoso, Oslo University Hospital, Rikshospitalet, Lutetium (177Lu) oxodotreotide, Medicine, Biobank, Somatostatin, FDA, Medical imaging

Differences in plasma-derived cell free DNA (cfDNA) 5hmC profiles after administration of Lutathera revealed biological responses consistent with radioligand therapy mechanism of action hypothesis.

Key Points: 
  • Differences in plasma-derived cell free DNA (cfDNA) 5hmC profiles after administration of Lutathera revealed biological responses consistent with radioligand therapy mechanism of action hypothesis.
  • “Our research collaboration with Novartis has demonstrated the power of ClearNote Health’s cutting-edge epigenomic technology in the interrogation of predictive biomarkers of radioligand therapy response from a single blood draw,” said Dave Mullarkey, CEO of ClearNote Health.
  • The comparison of plasma-derived cfDNA 5hmC profiles revealed differences that distinguish patients responding to therapy from those not responding before and on treatment.
  • This collaboration underscores ClearNote Health's commitment to empowering biopharmaceutical innovation in developing better drugs through cutting-edge molecular diagnostic technologies.

Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, March 19, 2024
Princess Margaret Cancer Centre, Detection, Interception, Nucleic acid thermodynamics, AACR, MRD, Sinai Health System, Biology, University Health Network

FOSTER CITY, Calif., March 19, 2024 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, today announced data will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024 from its tissue-agnostic minimal residual disease (MRD) assay. These data demonstrate the feasibility of the assay for cfDNA cancer signal quantification and prognostic prediction in HPV-positive and HPV-negative head & neck cancers following treatment. Data will also be presented on the analytical performance of Adela's platform.

Key Points: 
  • These data demonstrate the feasibility of the assay for cfDNA cancer signal quantification and prognostic prediction in HPV-positive and HPV-negative head & neck cancers following treatment.
  • Dr. De Carvalho will also present in the session "New Liquid Biopsy Technologies for Detection and Characterization of Cancer".
  • Adela plans to commercialize its first product, a tissue agnostic test for minimal residual disease (MRD) monitoring, in 2025.
  • It can be applied across the entire cancer care continuum and is initially being developed for MRD and multi-cancer early detection.

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

Retrieved on: 
Thursday, March 7, 2024
Insurance, FDA, Genetics, Public Relations, Investor Relations, Communications, Professional Services, Cardiology, Health Insurance, General Health, Health, Cohort (statistics), Lung, Risk, Nucleic acid thermodynamics, Medicare, Patient, Policy, Heart, Kidney, ProActive, BCBS, Publication, DNA, NTRA

The coverage policy includes serial testing with Prospera to assess graft status and identify the risk of rejection following a kidney or heart transplant.

Key Points: 
  • The coverage policy includes serial testing with Prospera to assess graft status and identify the risk of rejection following a kidney or heart transplant.
  • “Improving long-term outcomes for this population starts with more accurate and non-invasive tools to identify potential graft issues earlier.”
    Natera and its academic partners have published significant peer-reviewed evidence supporting the clinical utility of Prospera.
  • In addition, Natera has completed enrollment in the PEDAL and MOTR trials.
  • These are both multi-site, prospective studies designed to provide novel evidence supporting the clinical utility of Prospera, with expected publication in 2024.

Multi-Cancer Diagnostic Tests Market Outlook Report 2024: 2020-2023 Data and Compound Annual Growth Rate Projections Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024
Health, Oncology, Acquisition, Hospital, Forecasting, Cancer, Growth, ESG, Nucleic acid thermodynamics, Biomarker, Patient, MCD, Mortality, Research, DNA

The "Multi-Cancer Diagnostic Tests: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multi-Cancer Diagnostic Tests: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering.
  • This report aims to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for multi-cancer diagnostic tests.
  • This report provides a complete review and analysis of the current multi-cancer diagnostic (MCD) test market and industry growth drivers and challenges.
  • The market is segmented into laboratory-developed tests and in-vitro diagnostic tests based on test type.

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

Retrieved on: 
Wednesday, February 21, 2024
Technology, Health, General Health, Public Relations, Investor Relations, Communications, Health Technology, Medical Devices, Genetics, Internet, Mobile, Wireless, Clinical Trials, Hematopoietic stem cell transplantation, Caregiver, Patient, AML, Digital Solutions, ALL, HLA, Chimera, HCT, High, Medicine, Transplant, Prognosis, Cell, HA2, Nucleic acid thermodynamics, MDS, University, Antigen, HA1, Accuracy and precision, Medical device

“Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.

Key Points: 
  • “Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.
  • CareDx will be showcasing its broad portfolio of digital health solutions that address needs in the cellular transplant and therapy ecosystem including workflow management, regulatory reporting, medication management, and remote patient monitoring.
  • Product solution areas include:
    Ottr® Cellular: Designed as a workflow management solution for hematopoietic cellular transplant and cellular therapy centers.
  • Poster 299: Analytical Validation of AlloCell cfDNA - a Highly Sensitive, Precise, and Accurate Cell-Free DNA-Based Test for Allogeneic Cell Therapy Monitoring.

nRichDX to Debut New Products & Present Latest Research at AACR 2024 Annual Meeting this April

Retrieved on: 
Tuesday, February 20, 2024
SAN, Urine, OraSure Technologies, Revolution, CFRNA, Liquid biopsy, AACR, Annual general meeting, Nucleic acid thermodynamics, VAF, Agilent Technologies, Plasma, Diagnosis, San Diego Convention Center, Chinese, Prostate cancer

SAN DIEGO, Feb. 20, 2024 /PRNewswire/ -- nRichDX®, best known for the development of its Revolution Sample Prep System™, will be introducing new products, presenting new data, and exhibiting at the American Association for Cancer Research (AACR) 2024 Annual Meeting. Held April 5-10 at the San Diego Convention Center, the conference is dedicated to exploring and recognizing the latest discoveries in cancer research. nRichDX will exhibit in booth #3721, just inside the main registration entrance, and co-present three posters on April 8 & 9. Exhibits open at 1 PM on Sunday April 7 and close at 12:30 PM on Wednesday April 10.

Key Points: 
  • nRichDX will exhibit in booth #3721 , just inside the main registration entrance, and co-present three posters on April 8 & 9.
  • "nRichDX is proud to introduce the next generation of Revolution Sample Prep Instruments and Kits at this year's AACR Annual Meeting."
  • To meet with nRichDX people at AACR 2024 or schedule an in-booth demo, attendees are encouraged to schedule an appointment .
  • To find the latest information about nRichDX's schedule at AACR 2024, please visit nrichdx.com/aacr2024 .